Risk of Guillain-Barré Syndrome Following COVID-19 Vaccines: A Nationwide Self-Controlled Case Series Study.
Humans
Male
Child
Adolescent
Young Adult
Adult
Middle Aged
Female
Influenza, Human
/ complications
Influenza Vaccines
COVID-19 Vaccines
/ adverse effects
Ad26COVS1
Guillain-Barre Syndrome
/ epidemiology
COVID-19
/ epidemiology
Vaccination
/ adverse effects
ChAdOx1 nCoV-19
RNA, Messenger
mRNA Vaccines
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
21 Nov 2023
21 Nov 2023
Historique:
received:
07
04
2023
accepted:
03
08
2023
pmc-release:
21
11
2024
medline:
22
11
2023
pubmed:
4
10
2023
entrez:
3
10
2023
Statut:
ppublish
Résumé
Guillain-Barré syndrome (GBS) has been inconsistently associated with some coronavirus disease 2019 (COVID-19) vaccines. We aimed to quantify the risk of GBS according to the type of COVID-19 vaccine in a large population. Using the French National Health Data System linked to the COVID-19 vaccine database, we analyzed all individuals aged 12 years or older admitted for GBS from December 27, 2020, to May 20, 2022. We estimated the relative incidence (RI) of GBS within 1-42 days after vaccination up to the first booster dose compared with baseline periods using a self-controlled case series design. We then derived the number of cases attributable to the vaccination. Analyses were adjusted for the period and stratified by age group, sex, and for the presence of severe acute respiratory syndrome coronavirus 2 or common acute infections. Of 58,530,770 people aged 12 years or older, 88.8% received at least 1 COVID-19 vaccine dose and 2,229 were hospitalized for GBS during the study period. Patients had a median age of 57 years, and 60% were male patients. The RI of GBS between 1-42 days was 2.5 (95% CI 1.8-3.6) for the first dose of ChAdOx1-S and 2.4 (95% CI 1.2-5.0) for the unique dose of Ad26.COV2.S vaccine. We estimated 6.5 attributable GBS cases per million persons having received a first dose of ChAdOx1-S and 5.7 cases per million for the Ad26.COV2.S vaccine. Except for the age group of 12-49 years after the second dose of the messenger RNA (mRNA)-1273 vaccine (RI 2.6, 95% CI 1.2-5.5), none of the RI estimates were found significantly increased for the mRNA vaccines. In summary, we found increased risks of GBS after the first administration of ChAdOx1-S and Ad26.COV2.S vaccines. In this comprehensive assessment at the French population level, there was no statistically significant increase in the risk of GBS after the administration of mRNA vaccines. This is reassuring in the context of the ongoing and future use of mRNA-based booster vaccination.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Guillain-Barré syndrome (GBS) has been inconsistently associated with some coronavirus disease 2019 (COVID-19) vaccines. We aimed to quantify the risk of GBS according to the type of COVID-19 vaccine in a large population.
METHODS
METHODS
Using the French National Health Data System linked to the COVID-19 vaccine database, we analyzed all individuals aged 12 years or older admitted for GBS from December 27, 2020, to May 20, 2022. We estimated the relative incidence (RI) of GBS within 1-42 days after vaccination up to the first booster dose compared with baseline periods using a self-controlled case series design. We then derived the number of cases attributable to the vaccination. Analyses were adjusted for the period and stratified by age group, sex, and for the presence of severe acute respiratory syndrome coronavirus 2 or common acute infections.
RESULTS
RESULTS
Of 58,530,770 people aged 12 years or older, 88.8% received at least 1 COVID-19 vaccine dose and 2,229 were hospitalized for GBS during the study period. Patients had a median age of 57 years, and 60% were male patients. The RI of GBS between 1-42 days was 2.5 (95% CI 1.8-3.6) for the first dose of ChAdOx1-S and 2.4 (95% CI 1.2-5.0) for the unique dose of Ad26.COV2.S vaccine. We estimated 6.5 attributable GBS cases per million persons having received a first dose of ChAdOx1-S and 5.7 cases per million for the Ad26.COV2.S vaccine. Except for the age group of 12-49 years after the second dose of the messenger RNA (mRNA)-1273 vaccine (RI 2.6, 95% CI 1.2-5.5), none of the RI estimates were found significantly increased for the mRNA vaccines.
DISCUSSION
CONCLUSIONS
In summary, we found increased risks of GBS after the first administration of ChAdOx1-S and Ad26.COV2.S vaccines. In this comprehensive assessment at the French population level, there was no statistically significant increase in the risk of GBS after the administration of mRNA vaccines. This is reassuring in the context of the ongoing and future use of mRNA-based booster vaccination.
Identifiants
pubmed: 37788935
pii: WNL.0000000000207847
doi: 10.1212/WNL.0000000000207847
pmc: PMC10663040
doi:
Substances chimiques
Influenza Vaccines
0
COVID-19 Vaccines
0
Ad26COVS1
JT2NS6183B
ChAdOx1 nCoV-19
B5S3K2V0G8
RNA, Messenger
0
mRNA Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2094-e2102Informations de copyright
© 2023 American Academy of Neurology.
Références
Neurologia (Engl Ed). 2020 Nov - Dec;35(9):646-654
pubmed: 32896460
N Engl J Med. 2012 Jun 14;366(24):2294-304
pubmed: 22694000
Am J Epidemiol. 1991 May 1;133(9):940-51
pubmed: 1851395
Brain. 2023 Feb 13;146(2):739-748
pubmed: 35180300
BMJ. 2022 Mar 16;376:e068373
pubmed: 35296468
Lancet. 2016 Apr 9;387(10027):1531-1539
pubmed: 26948433
Vaccine. 2022 Jul 30;40(32):4479-4487
pubmed: 35715350
Lancet Reg Health Eur. 2021 Sep;8:100158
pubmed: 34308411
Neurology. 2020 May 19;94(20):e2168-e2179
pubmed: 32098853
N Engl J Med. 2020 Jun 25;382(26):2574-2576
pubmed: 32302082
JAMA Netw Open. 2023 Feb 1;6(2):e2253845
pubmed: 36723942
Int J Epidemiol. 2017 Apr 1;46(2):392-392d
pubmed: 28168290
JAMA Netw Open. 2022 Apr 1;5(4):e228879
pubmed: 35471572
Stat Med. 2022 May 10;41(10):1735-1750
pubmed: 35092037
J Peripher Nerv Syst. 2017 Mar;22(1):51-58
pubmed: 27991707
JAMA. 2021 Oct 26;326(16):1606-1613
pubmed: 34617967
Neurology. 2018 Sep 25;91(13):e1220-e1227
pubmed: 30143563
Nat Med. 2021 Dec;27(12):2144-2153
pubmed: 34697502
Lancet. 2021 Mar 27;397(10280):1214-1228
pubmed: 33647239
Ann Intern Med. 2022 Sep;175(9):1250-1257
pubmed: 35994748
Nat Med. 2022 Nov;28(11):2406-2415
pubmed: 36138154
Neuroepidemiology. 2011;36(2):123-33
pubmed: 21422765
Biostatistics. 2009 Jan;10(1):3-16
pubmed: 18499654